DXNVX Wins International Design Award Gold for Chinese Antibiotic Product

DXVX recently announced on the 19th that its Dx&Vx Azithromycin antibiotic product won the Gold Award in the package design category at the London Design Awards, hosted by the International Awards Association (IAA).

The awarded Dx&Vx Azithromycin antibiotic, as a pharmaceutical product, is subject to strict government regulations on advertising and imagery, which inevitably limits the scope of design expression. The company stated, “We unexpectedly received this award,” adding, “We consider packaging design as part of the quality management we pursue, and this achievement is the result of our best efforts to provide information within strict regulations while maintaining quality control.”

IAA stands for ‘Inspire, Advance, Achieve’ and was established in 2016. It comprises over 200 international judges from 112 countries. In the 2023 London Design Awards, more than 1,200 entries from over 30 countries including the United States, the United Kingdom, and Germany were submitted.

At this year’s London Design Awards, in addition to the DXVX brand antibiotic design, several consumer products from DXVX and the Kori Group also won Gold Awards in package design. These include Formulamate-Ofmom, Ofmom infant formula series, U-ZA skincare series, and Sanita-Denti infant toothpaste series.

A representative from DXVX said, “As our company and the Kori Group expand their brands into the global market, we have been recognized not only for competitiveness in quality but also for global-level competitiveness in design, which can be a strong appeal point for consumer products. Since packaging and package design are important factors in consumer purchase decisions, we consider this as part of the quality management we pursue and will continue to do our best.”

Meanwhile, DXVX began selling its own antibiotic products in July through its Chinese subsidiary Dx&Vx BJ in the Chinese antibiotic market, which is worth approximately 37 trillion KRW annually. The company plans to expand its lineup with various basic pharmaceuticals such as treatments for skin diseases, arthritis supplements, oral inflammation treatments, and ophthalmic disease supplements, as well as expand its portfolio with best-in-class products and new drugs.

This content was produced with the assistance of AI translation services.